Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

Matza Louis S.; Cutts Katelyn N.; Stewart Katie D.Norrbacka KirsiGarcia-Perez Luis-EmilioBoye Kristina S.

首页> 外文期刊>Quality of life research: An international journal of quality of life aspects of treatment, care and rehabilitation >Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

【24h】

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

机译：Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Purpose Previous research suggests that treatment process can have an influence on patient preference and health state utilities. This study examined preferences and estimated utilities for treatment processes of two daily oral treatment regimens and two weekly injectable regimens for treatment of type 2 diabetes (T2D).

著录项

来源
《Quality of life research: An international journal of quality of life aspects of treatment, care and rehabilitation》 |2021年第7期|2033-2043|共11页
作者
Matza Louis S.; Cutts Katelyn N.; Stewart Katie D.Norrbacka KirsiGarcia-Perez Luis-EmilioBoye Kristina S.;
展开▼
作者单位

Evidera, Patient Ctr Res, 7101 Wisconsin Ave,Suite 1400, Bethesda, MD 20814 USA;

Eli Lilly Finland, Helsinki, Finland;

Lilly SA, Alcobendas, SpainEli Lilly & Co, Indianapolis, IN 46285 USA;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类医药、卫生;
关键词
(4-6): Health state utility; Treatment process utility; Utility; Route of administration; Type 2 diabetes; Glucagon-like peptide-1 receptor agonist; GLP-1 RA;

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

摘要

著录项

相关主题

期刊订阅